Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

T2Lead

Financiado

Define a lead candidate for clinical development of a novel T cell therapy

Acute myeloid leukemia (AML) is a disease with a poor prognosis, especially for such patients either failing initial treatment or relapsing thereafter. In AML, specific immune cells such as T cells have been proven to bear curativ... ver más

28/02/2025

LMU MUENCHEN

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-13

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2 Objective:Objectives:

I+D

Cerrada hace 2 años

0% 100% 100%

2 Participantes

LMU MUENCHEN

150.00K€ | Lider

EIT Urban Mobility Innovatio...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PTQ2020-011056 Identificación de dianas terapéuticas universales para la le... 37K€ Cerrado

TTT-therapy Targeting Acute Leukemia with TdT-TCR-T-cell therapy 150K€ Cerrado

CARxALL Next generation, off-the-shelf, non fratricide-directed, CAR... 2M€ Cerrado

PTQ2021-011893 Generación de células T efectoras VD1+gd derivadas de sangre... 90K€ Cerrado

ArTCell Bottom-up manufacturing of artificial anti-tumor T cells 3M€ Cerrado

PID2019-109546RA-I00 CELULAS T GENETICAMENTE MODIFICADAS PARA EXPRESAR RECEPTORES... 163K€ Cerrado

Duración del proyecto: 23 meses Fecha Inicio: 2023-03-13
Fecha Fin: 2025-02-28

Líder del proyecto

LUDWIGMAXIMILIANSUNIVERSITAET MUENCHEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Acute myeloid leukemia (AML) is a disease with a poor prognosis, especially for such patients either failing initial treatment or relapsing thereafter. In AML, specific immune cells such as T cells have been proven to bear curative potential in the context of stem cell transplantation but toxicity and therapy failure are frequent. The use of T cells modified for specificity with chimeric antigen receptors (CAR) has changed the landscape of several blood-borne cancer of the B cell lineage. In AML, however, ongoing development of CAR T cells is associated with severe toxicities, limiting dosing and efficacy because of poor specificity of used targets for AML blasts. In my ERC funded research, I have identified unique AML targets which are not shared with healthy hematopoesis or other relevant healthy organs. Developing CAR against these, I could demonstrate the potential of my strategy. To enable clinical development and exploitation, T2LEAD will identify and develop lead CAR candidates for further translation. T2LEAD will explore the medical and commercial potential of lead CAR and route exploitation towards licensing or spin out or both. T2LEAD will be supported by a strong network of advisors from academia, industry and regulation frame work. Ultimately T2LEAD will help advancing the treatment landscape in AML to the benefit of AML patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores